Skip to Content
Merck
CN

S5521

Suxibuzone

Synonym(s):

4-Butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate (ester)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C24H26N2O6
CAS Number:
Molecular Weight:
438.47
UNSPSC Code:
12352202
PubChem Substance ID:
EC Number:
248-477-6
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


form

solid

SMILES string

CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c2ccccc2)c3ccccc3

InChI

1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)

InChI key

ONWXNHPOAGOMTG-UHFFFAOYSA-N

Biochem/physiol Actions

A prodrug of phenylbutazone.


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(suxibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)].
T Shindo et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 99(12), 1186-1200 (1979-12-01)
[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].
K Taira et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 100(3), 272-279 (1980-03-01)
S Yanagi et al.
Cancer letters, 36(1), 11-18 (1987-07-01)
Among phenylbutazone (PZ) and its related compounds, suxibuzone (SUX) caused the most extensive decrease in pyruvate kinase (PK) activity with lower toxicity. Therefore, we studied the effect of SUX on rat hepatocarcinogenesis to confirm our assumption that an agent which